2024-10-22 - Analysis Report
## Amgen Inc (AMGN) Stock Analysis Report

**1. Performance Comparison:**

Amgen Inc (AMGN) has a cumulative return of 79.88%, lagging behind the S&P 500 (VOO) with a cumulative return of 137.88%.  The current performance gap is -58.0, which represents the 28.12 percentile of historical performance gaps between the two.

**2. Recent Price Movement:**

* Closing Price: $321.66
* 5-day Moving Average: $322.87
* 20-day Moving Average: $322.45
* 60-day Moving Average: $326.54

The stock is currently trading below all three moving averages, indicating potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 49.12 -  The RSI is close to the neutral level of 50, suggesting neither strong overbought nor oversold conditions. 
* **PPO:** 0.06 - A positive PPO suggests a possible uptrend, however, the value is quite low, indicating a weak trend.
* **Delta_Previous_Relative_Divergence:** -14.19 - The negative value indicates a short-term downward trend in relative performance.
* **Expected Return:** 0.0% - The expected return over the long term (2+ years) is currently estimated to be neutral compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date       | EPS   | Revenue |
|------------|-------|---------|
| 2024-08-07 | 1.39  | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23  | 6.90 B$ |
| 2023-08-04 | 2.58  | 6.99 B$ |
| 2024-08-07 | 2.58  | 6.99 B$ |

The latest earnings report (2024-08-07) showed an EPS of 1.39, exceeding the analyst estimates by a significant margin. The revenue also surpassed expectations at 8.39 B$.  The company's strong recent performance indicates a positive trajectory.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Amgen's stock price has been relatively stable in recent months, with investors showing some optimism about the company's future prospects. 
* **Analyst Opinions:**  Analysts have generally given AMGN a "buy" rating, highlighting its strong market position, robust pipeline of new drugs, and potential for growth in the biopharmaceutical industry.
* **Performance Highlights:** Amgen has recently achieved several milestones, including the approval of new drugs, and is expected to continue innovating and expanding its product portfolio.  

**6. Overall Analysis:**

Amgen is a leading biopharmaceutical company with a strong track record and a promising future. Despite the recent underperformance compared to the S&P 500, the company's strong earnings, positive analyst sentiment, and continued innovation suggest that AMGN has the potential to outperform in the long run.  While the current technical indicators indicate potential short-term weakness, long-term investors may find AMGN to be a suitable addition to their portfolio.

**7. Summary:**

Amgen Inc is a leading biopharmaceutical company with a strong market position and robust pipeline. Despite recent underperformance compared to the S&P 500, the company's strong earnings, positive analyst sentiment, and continued innovation suggest long-term potential. Investors seeking exposure to the biopharmaceutical sector may consider AMGN, taking into account its current technical indicators and potential short-term headwinds.
